Charles River Laboratories International (CRL) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
Research notes will appear with the next update.
What does Charles River Laboratories International (CRL) do?
Charles River Laboratories International Inc (CRL) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Breeds and sells specialized research model animals for biomedical studies. Supplies laboratory animals and conducts early-stage testing services for pharmaceutical and biotechnology drug. It is worth $15.71B on the market and sold $3.98B over the last year.
- Market cap
- $15.71B
- P/E ratio
- 363.5×
- Annual sales
- $3.98B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 14, 2026
Brands and businesses behind CRL
- Endosafe: Sells instruments and test cartridges to pharmaceutical manufacturers to detect bacterial toxins in injectable drugs.
- Accugenix: Provides microbial identification testing services and genomic databases to track contamination in manufacturing cleanrooms.
- Celsis: Sells rapid screening systems and reagents to confirm sterility in consumer products and drug manufacturing.
CRL’s flags, in plain English
Each flag is a number from Charles River Laboratories International’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Priced for Perfection
Priced at 363.5 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
Questions about CRL
How big is Charles River Laboratories International?
Charles River Laboratories International’s market cap is $15.71B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.98B: what customers paid the company over the last year, before any costs.
What is CRL’s P/E ratio?
CRL’s P/E ratio is 363.5×. Investors pay about 363.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with CRL?
The business faces legal investigations and supply disruptions concerning non-human primate imports used in drug safety studies. That is one risk on Charles River Laboratories International’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Charles River Laboratories International’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CRL’s filings on SEC.gov. The Margin Monkey is research, not advice.
